Publicaciones en colaboración con investigadores/as de Fondazione IRCCS Istituto Nazionale dei Tumori (15)

2024

  1. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis

    Journal of Hepatology

  2. The Alpha-Lipoic Acid Improves Glucose Metabolism and Hyperinsulinemia in Acute Intermittent Porphyria: A Nutritional Concept for the Management of Rare Disorders

    Cellular and Molecular Gastroenterology and Hepatology

2023

  1. Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 50, Núm. 2, pp. 328-343

  2. Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 50, Núm. 3, pp. 921-928

2022

  1. De Novo Malignancy after Liver Transplantation: Risk Assessment, Prevention, and Management - Guidelines from the ILTS-SETH Consensus Conference

    Transplantation, Vol. 106, Núm. 1, pp. E30-E45

  2. The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

    The Lancet, Vol. 399, Núm. 10319, pp. 61-116

2021

  1. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

    Journal of Clinical Oncology, Vol. 39, Núm. 27, pp. 2991-3001

2020

  1. Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference

    Transplantation, Vol. 104, Núm. 6, pp. 1143-1149

2019

  1. Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges

    Journal of Thoracic Oncology, Vol. 14, Núm. 3, pp. 343-357

2015

  1. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey

    Clinical Microbiology and Infection, Vol. 21, Núm. 6, pp. 604.e1-604.e9

2013

  1. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives

    Hepatology, Vol. 58, Núm. 6, pp. 2188-2197

2012

  1. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: Proposal for a subclassification to facilitate treatment decisions

    Seminars in Liver Disease, Vol. 32, Núm. 4, pp. 348-359

2011

  1. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization

    Cancer Treatment Reviews, Vol. 37, Núm. 3, pp. 212-220

  2. Research reporting standards for radioembolization of hepatic malignancies

    Journal of Vascular and Interventional Radiology, Vol. 22, Núm. 3, pp. 265-278

2006

  1. Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma

    Cancer Research, Vol. 66, Núm. 4, pp. 2442-2450